The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABIO Detailed Price Forecast - CNN Money||View ABIO Detailed Summary - Google Finance|
|View ABIO Detailed Summary - Yahoo! Finance||View ABIO Stock Research & Analysis - Zacks.com|
|View ABIO Trends & Analysis - Trade-Ideas||View ABIO Major Holders - Barrons|
|View ABIO Call Transcripts - NASDAQ||View ABIO Breaking News & Analysis - Seeking Alpha|
|View ABIO Annual Report - CompanySpotlight.com||View ABIO OTC Short Report - OTCShortReport.com|
|View ABIO Fundamentals - TradeKing||View ABIO SEC Filings - Bar Chart|
|View Historical Prices for ABIO - The WSJ||View Performance/Total Return for ABIO - Morningstar|
|View the Analyst Estimates for ABIO - MarketWatch||View the Earnings History for ABIO - CNBC|
|View the ABIO Earnings - StockMarketWatch||View ABIO Buy or Sell Recommendations - MacroAxis|
|View the ABIO Bullish Patterns - American Bulls||View ABIO Short Pain Metrics - ShortPainBot.com|
|View ABIO Stock Mentions - StockTwits||View ABIO Stock Mentions - PennyStockTweets|
|View ABIO Stock Mentions - Twitter||View ABIO Investment Forum News - Investor Hub|
|View ABIO Stock Mentions - Yahoo! Message Board||View ABIO Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABIO - SECform4.com||View Insider Transactions for ABIO - Insider Cow|
|View ABIO Major Holdings Summary - CNBC||View Insider Disclosure for ABIO - OTC Markets|
|View Insider Transactions for ABIO - Yahoo! Finance||View Institutional Holdings for ABIO - NASDAQ|
|View ABIO Stock Insight & Charts - FinViz.com||View ABIO Investment Charts - StockCharts.com|
|View ABIO Stock Overview & Charts - BarChart||View ABIO User Generated Charts - Trading View|
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Posted on Wednesday January 16, 2019
Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies.
ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
Posted on Wednesday December 26, 2018
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
Posted on Thursday December 20, 2018
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted an amendment to its Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA). The amendment addresses FDA feedback and guidance on the target population for ARCA’s planned Phase 3 clinical trial. The SPA request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure (HF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.
ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Posted on Wednesday November 14, 2018
WESTMINSTER, Colo., Nov. 14, 2018 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.